Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epanova and Rosuvastatin Interaction and Comparison with Vascepa
NCT02859129Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2013
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Omega-3 carboxylic acids in hypertriglyceridemia (2 cohorts), sponsored by AstraZeneca. Primary endpoints: Steady-state Maximum Plasma Concentration at Day 24 and Area Under the Curve over dosing interval at Day 24. Started Sep 2013; status: completed.
02
Drugs
Omega-3 carboxylic acids
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT02859129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859129.